ImmuPharma PLC
Research ImmuPharma PLC (IMM) on Bullrun: market cap GBX 2.14B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMM
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 2.14B
- Financial periodFY2025
Valuation Snapshot
latest market cap is GBX 2.14B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | -0.04 | n/a | n/a | n/a |
| FY2024 | GBP 0 | -GBP 2.48M | -GBP 1.77M | n/a | -0.01 | GBP 236.90K | GBP 1.59M | -GBP 542.86K |
| FY2023 | GBP 0 | -GBP 2.92M | -GBP 1.36M | n/a | -0.01 | GBP 208.48K | GBP 0 | GBP 1.06M |
| FY2022 | GBP 0 | -GBP 3.81M | -GBP 2.45M | n/a | -0.01 | GBP 667.81K | GBP 111 | GBP 2.52M |
| FY2021 | GBP 118.35K | -GBP 8.17M | -GBP 4.88M | n/a | -0.03 | GBP 1.65M | GBP 700 | GBP 4.41M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-28 | GBX 2.14B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About ImmuPharma PLC
ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally. It develops P140, a peptide-based therapy, which is in clinical trial for the treatment of autoimmune and inflammatory diseases, as well as various therapeutic areas, including dermatology, gastroenterology, rheumatology, endocrinology, and neurology;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ImmuPharma PLC's market cap?
ImmuPharma PLC's market capitalization is GBX 2.14B.
What does ImmuPharma PLC do?
ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally.